PIK3CG and acute leukemia: Despite this encouraging preclinical data and the unmet clinical need in patients with acute leukemia who have relapsed or are refractory to induction treatment, no clinical trials of PI3K pathway inhibitors other than the mTORC1 inhibitor RAD001 have to our knowledge been conducted in patients with acute leukemia.